Cerebral Ischemia and Inflammation

Stroke: Pathophysiology, Diagnosis, and Management

Volumn , Issue , 2004, Pages 883-893

  Iadecola, Costantino ^a   Cho, Sunghee ^a   Feuerstein, Giora Z ^b   Hallenbeck, John ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942595447     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-44-306600-0/50052-3     Document Type: Chapter

References (142)

1. Barone FC, Feuerstein GZ Inflammatory mediators and stroke: New opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999, 19:819.
2. del Zoppo G, Ginis I, Hallenbeck JM, et al. Inflammation and stroke: Putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 2000, 10:95.
3. Lipton P Ischemic cell death in brain neurons. Physiol Rev 1999, 79:1431.
4. Allan SM, Rothwell NJ Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2:734.
5. Emerich DF, Dean RL, Bartus RT The role of leukocytes following cerebral ischemia: Pathogenic variable or bystander reaction to emerging infarct?. Exp Neurol 2002, 173:168.
6. Dirnagl U, Iadecola C, Moskowitz MA Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 1999, 22:391.
7. Kostulas N, Pelidou SH, Kivisakk P, et al. Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 1999, 30:2174.
8. Pelidou SH, Kostulas N, Matusevicius D, et al. High levels of IL-10 secreting cells are present in blood in cerebrovascular diseases. Eur J Neurol 1999, 6:437.
9. Ritter LS, Orozco JA, Coull BM, et al. Leukocyte accumulation and hemodynamic changes in the cerebral microcirculation during early reperfusion after stroke. Stroke 2000, 31:1153.
10. Peters E, Feuerstein G Chemokines and ischemic stroke. Inflammation and Stroke 2001, 155. Birkhauser, New York. G. Feuerstein (Ed.).
11. Heinel LA, Rubin S, Rosenwasser RH, et al. Leukocyte involvement in cerebral infarct generation after ischemia and reperfusion. Brain Res Bull 1994, 34:137.
12. Matsuo Y, Onodera H, Shiga Y, et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemia brain injury in the rat. Stroke 1994, 25:1469.
13. Jiang N, Moyle M, Soule HR, et al. Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats. Ann Neurol 1995, 38:935.
14. Zhang RL, Chopp M, Li Y, et al. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 1994, 44:1747.
15. Mori E, del Zoppo GJ, Chambers JD, et al. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke 1992, 23:712.
16. Chen H, Chopp M, Zhang RL, et al. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol 1994, 35:458.
17. Zhang RL, Chopp M, Zhang ZG, et al. E-selectin in focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab 1996, 16:1126.
18. Morikawa E, Zhang SM, Seko Y, et al. Treatment of focal cerebral ischemia with synthetic oligopeptide corresponding to lectin domain of selectin. Stroke 1996, 27:951.
19. Suzuki H, Hayashi T, Tojo SJ, et al. Anti-P-selectin antibody attenuates rat brain ischemic injury. Neurosci Lett 1999, 265:163.
20. Connolly ES, Winfree CJ, Prestigiacomo CJ, et al. Exacerbation of cerebral injury in mice that express the P-selectin gene: Identification of P-selectin blockade as a new target for the treatment of stroke. Circ Res 1997, 81:304.
21. Soriano SG, Coxon A, Wang YF, et al. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke 1999, 30:134.
22. Connolly ES, Winfree CJ, Springer TA, et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion: Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996, 97:209.
23. Dawson DA, Martin D, Hallenbeck JM Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett 1996, 218:41.
24. Yang GY, Gong C, Qin Z, et al. Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport 1998, 9:2131.
25. Yamasaki Y, Matsuura N, Shozuhara H, et al. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995, 26:676.
26. Loddick SA, Rothwell NJ Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1996, 16:932.
27. Loddick SA, Turnbull AV, Rothwell NJ Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1998, 18:176.
28. Yang GY, Schielke GP, Gong C, et al. Expression of tumor necrosis factor-alpha and intercellular adhesion molecule-1 after focal cerebral ischemia in interleukin-1beta converting enzyme deficient mice. J Cereb Blood Flow Metab 1999, 19:1109.
29. Matsumoto T, Ikeda K, Mukaida N, et al. Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8. Lab Invest 1997, 77:119.
30. Yamasaki Y, Matsuo Y, Zagorski J, et al. New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats. Brain Res 1997, 759:103.
31. Del Zoppo GJ, Schmid-Schonbein GW, Mori E, et al. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991, 22:1276.
32. Ahmed SH, He YY, Nassief A, et al. Effects of lipopolysaccharide priming on acute ischemic brain injury. Stroke 2000, 31:193.
33. Buttini M, Sauter A, Boddeke HW Induction of interleukin-1 beta mRNA after focal cerebral ischaemia in the rat. Brain Res Mol Brain Res 1994, 23:126.
34. Liu T, McDonnell PC, Young PR, et al. Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke 1993, 24:1746.
35. Liu T, Clark RK, McDonnell PC, et al. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 1994, 25:1481.
36. Wang X, Yue TL, Barone FC, et al. Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Mol Chem Neuropathol 1994, 23:103.
37. Minami M, Kuraishi Y, Yabuuchi K, et al. Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia. J Neurochem 1992, 58:390.
38. Yabuuchi K, Minami M, Katsumata S, et al. An in situ hybridization study on interleukin-1 beta mRNA induced by transient forebrain ischemia in the rat brain. Brain Res Mol Brain Res 1994, 26:135.
39. Saito K, Suyama K, Nishida K, et al. Early increases in TNF-alpha, IL-6 and IL-1 beta levels following transient cerebral ischemia in gerbil brain. Neurosci Lett 1996, 206:149.
40. Uno H, Matsuyama T, Akita H, et al. Induction of tumor necrosis factor-alpha in the mouse hippocampus following transient forebrain ischemia. J Cereb Blood Flow Metab 1997, 17:491.
41. Barone FC, Arvin B, White RF, et al. Tumor necrosis factor-alpha: A mediator of focal ischemic brain injury. Stroke 1997, 28:1233.
42. Garcia JH, Liu KF, Relton JK Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am J Pathol 1995, 147:1477.
43. Relton JK, Rothwell NJ Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992, 29:243.
44. Rothwell NJ, Relton JK Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage. Cerebrovasc Brain Metab Rev 1993, 5:178.
45. Martin D, Chinookoswong N, Miller G The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp Neurol 1994, 130:362.
46. Betz AL, Yang GY, Davidson BL Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J Cereb Blood Flow Metab 1995, 15:547.
47. Basu A, Krady JK, O'Malley M, et al. The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J Neurosci 2002, 22:6071.
48. Liu J, Ginis I, Spatz M, et al. Hypoxic preconditioning protects cultured neurons against hypoxic stress via TNF-alpha and ceramide. Am J Physiol Cell Physiol 2000, 278:C144.
49. Bruce AJ, Boling W, Kindy MS, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996, 2:788.
50. Yang L, Lindholm K, Konishi Y, et al. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 2002, 22:3025.
51. Fontaine V, Mohand-Said S, Hanoteau N, et al. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: Opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002, 22:RC216.
52. Martin-Villalba A, Hahne M, Kleber S, et al. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 2001, 8:679.
53. Iadecola C The role of NO in cerebrovascular regulation and stroke. The Haemodynamic Effects of Nitric Oxide 1999, 202. Imperial College Press, London. R.T. Mathie, T.M. Griffith (Eds.).
54. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990, 87:1620.
55. Iadecola C, Zhang F, Xu X, et al. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 1995, 15:378.
56. Iadecola C, Zhang F, Casey R, et al. Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke 1996, 27:1373.
57. Grandati M, Verrecchia C, Revaud ML, et al. Calcium-independent NO-synthase activity and nitrites/nitrates production in transient focal cerebral ischaemia in mice. Br J Pharmacol 1997, 122:625.
58. Hirabayashi H, Takizawa S, Fukuyama N, et al. Nitrotyrosine generation via inducible nitric oxide synthase in vascular wall in focal ischemia-reperfusion. Brain Res 2000, 852:319.
59. Forster C, Clark HB, Ross ME, et al. Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol (Berl) 1999, 97:215.
60. Tarkowski E, Ringqvist A, Rosengren L, et al. Intrathecal release of nitric oxide and its relation to final brain damage in patients with stroke. Cerebrovasc Dis 2000, 10:200.
61. Iadecola C, Zhang F, Xu X Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol 1995, 268:R286.
62. Nagayama M, Zhang F, Iadecola C Delayed treatment with aminoguanidine decreases focal cerebral ischemic damage and enhances neurologic recovery in rats. J Cereb Blood Flow Metab 1998, 18:1107.
63. Parmentier S, Bohme GA, Lerouet D, et al. Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. Br J Pharmacol 1999, 127:546.
64. Zhao X, Haensel C, Araki E, et al. Gene-dosing effect and persistence of reduction in ischemic brain injury in mice lacking inducible nitric oxide synthase. Brain Res 2000, 872:215.
65. Iadecola C, Zhang F, Casey R, et al. Delayed reduction in ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997, 17:9157.
66. Parmentier-Batteur S, Bohme GA, Lerouet D, et al. Antisense oligodeoxynucleotide to inducible nitric oxide synthase protects against transient focal cerebral ischemia-induced brain injury. J Cereb Blood Flow Metab 2001, 21:15.
67. Vane JR, Bakhle YS, Botting RM Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97.
68. O'Banion MK Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999, 13:45.
69. Miettinen S, Fusco FR, Yrjanheikki J, et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci U S A 1997, 94:6500.
70. Nogawa S, Zhang F, Ross ME, et al. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997, 17:2746.
71. Nogawa S, Forster C, Zhang F, et al. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci U S A 1998, 95:10966.
72. Iadecola C, Forster C, Nogawa S, et al. Cyclooxygenase immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol 1999, 98:9.
73. Sairanen T, Ristimaki A, Karjalainen-Lindsberg ML, et al. Cyclooxygenase-2 is induced globally in infarcted human brain. Ann Neurol 1998, 43:738.
74. Nagayama M, Niwa K, Nagayama T, et al. The cyclooxygenase-2 inhibitor NS-398 ameliorates cerebral ischemic injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999, 19:1213.
75. Iadecola C, Niwa K, Nogawa S, et al. Reduced susceptibility to ischemic brain injury and NMDA-mediated neurotoxicity in cyclooxygenase-2 deficient mice. Proc Natl Acad Sci U S A 2001, 98:1294.
76. Salvemini D, Seibert K, Masferrer JL, et al. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 1994, 93:1940.
77. Mattson MP, Culmsee C, Yu Z, et al. Roles of nuclear factor kappaB in neuronal survival and plasticity. J Neurochem 2000, 74:443.
78. Baeuerle PA, Baltimore D NF-kappa B: Ten years after. Cell 1996, 87:13.
79. Salminen A, Liu PK, Hsu CY Alteration of transcription factor binding activities in the ischemic rat brain. Biochem Biophys Res Commun 1995, 212:939.
80. Carroll JE, Hess DC, Howard EF, et al. Is nuclear factor-kappaB a good treatment target in brain ischemia/reperfusion injury?. Neuroreport 2000, 11:R1.
81. Gabriel C, Justicia C, Camins A, et al. Activation of nuclear factor-kappaB in the rat brain after transient focal ischemia. Brain Res Mol Brain Res 1999, 65:61.
82. Stephenson D, Yin T, Smalstig EB, et al. Transcription factor nuclear factor-kappa B is activated in neurons after focal cerebral ischemia. J Cereb Blood Flow Metab 2000, 20:592.
83. Schneider A, Martin-Villalba A, Weih F, et al. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 1999, 5:554.
84. Terai K, Matsuo A, McGeer EG, et al. Enhancement of immunoreactivity for NF-kappa B in human cerebral infarctions. Brain Res 1996, 739:343.
85. Carroll JE, Howard EF, Hess DC, et al. Nuclear factor-kappa B activation during cerebral reperfusion: Effect of attenuation with N-acetylcysteine treatment. Brain Res Mol Brain Res 1998, 56:186.
86. Buchan AM, Li H, Blackburn B Neuroprotection achieved with a novel proteosome inhibitor which blocks NF-kappaB activation. Neuroreport 2000, 11:427.
87. Yu Z, Zhou D, Bruce-Keller AJ, et al. Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury. J Neurosci 1999, 19:8856.
88. Taniguchi T, Ogasawara K, Takaoka A, et al. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001, 19:623.
89. Paschen W, Gissel C, Althausen S, et al. Changes in interferon-regulatory factor-1 mRNA levels after transient ischemia in rat brain. Neuroreport 1998, 9:3147.
90. Iadecola C, Salkowski CA, Zhang F, et al. The transcription factor interferon regulatory factor 1 is expressed after cerebral ischemia and contributes to ischemic brain injury. J Exp Med 1999, 189:719.
91. Iadecola C, Alexander M, Nogawa S, et al. Inflammation-related genes and ischemic brain injury. Pharmacology of Cerebral Ischemia 2000 2000, 241. Medpharm Scientific Publishers, Stuttgart. J. Klumpp (Ed.).
92. Gaal J Cellular euthanasia mediated by a nuclear enzyme: A central role for nuclear ADP-ribosylation in cellular metabolism. Trends Biochem Sci 1987, 12:129.
93. Pieper AA, Verma A, Zhang J, et al. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999, 20:171.
94. Szabo C, Dawson VL Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 1998, 19:287.
95. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297:259.
96. Chiarugi A Poly(ADP-ribose) polymerase: Killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol Sci 2002, 23:122.
97. Oliver FJ, Menissier-de Murcia J, Nacci C, et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 1999, 18:4446.
98. Hassa PO, Hottiger MO A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol Chem 1999, 380:953.
99. Le Page C, Sanceau J, Drapier JC, et al. Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF kappa B activation. Biochem Biophys Res Commun 1998, 243:451.
100. Takahashi K, Pieper AA, Croul SE, et al. Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia. Brain Res 1999, 829:46.
101. Takahashi K, Greenberg JH, Jackson P, et al. Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1997, 17:1137.
102. Eliasson MJ, Sampei K, Mandir AS, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 1997, 3:1089.
103. Bahr RD, Leino EV, Christenson RH Prodromal unstable angina in acute myocardial infarction: Prognostic value of short- and long-term outcome and predictor of infarct size. Am Heart J 2000, 140:126.
104. Noda T, Minatoguchi S, Fujii K, et al. Evidence for the delayed effect in human ischemic preconditioning: Prospective multicenter study for preconditioning in acute myocardial infarction. J Am Coll Cardiol 1999, 34:1966.
105. Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size: A role for ischemic preconditioning. Circulation 1995, 91:291.
106. Murry CE, Jennings RB, Reimer KA Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124.
107. Kitagawa K, Matsumoto M, Tagaya M, et al. 'Ischemic tolerance' phenomenon found in the brain. Brain Res 1990, 528:21.
108. Weih M, Kallenberg K, Bergk A, et al. Attenuated stroke severity after prodromal TIA: A role for ischemic tolerance in the brain?. Stroke 1999, 30:1851.
109. Moncayo J, de Freitas GR, Bogousslavsky J, et al. Do transient ischemic attacks have a neuroprotective effect?. Neurology 2000, 54:2089.
110. Schobitz B, De Kloet ER, Holsboer F Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Prog Neurobiol 1994, 44:397.
111. Ohtsuki T, Ruetzler CA, Tasaki K, et al. Interleukin-1 mediates induction of tolerance to global ischemia in gerbil hippocampal CA1 neurons. J Cereb Blood Flow Metab 1996, 16:1137.
112. Song W, Furman BL, Parratt JR Delayed protection against ischaemia-induced ventricular arrhythmias and infarct size limitation by the prior administration of Escherichia coli endotoxin. Br J Pharmacol 1996, 118:2157.
113. Eising GP, Mao L, Schmid-Schonbein GW, et al. Effects of induced tolerance to bacterial lipopolysaccharide on myocardial infarct size in rats. Cardiovasc Res 1996, 31:73.
114. Rowland RT, Meng X, Cleveland JC, et al. LPS-induced delayed myocardial adaptation enhances acute preconditioning to optimize postischemic cardiac function. Am J Physiol 1997, 272:H2708.
115. Tasaki K, Ruetzler CA, Ohtsuki T, et al. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 1997, 748:267.
116. Puisieux F, Deplanque D, Pu Q, et al. Differential role of nitric oxide pathway and heat shock protein in preconditioning and lipopolysaccharide-induced brain ischemic tolerance. Eur J Pharmacol 2000, 389:71.
117. Bordet R, Deplanque D, Maboudou P, et al. Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide-induced brain ischemic tolerance. J Cereb Blood Flow Metab 2000, 20:1190.
118. Wong GH, Elwell JH, Oberley LW, et al. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 1989, 58:923.
119. Eddy LJ, Goeddel DV, Wong GH Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun 1992, 184:1056.
120. Nawashiro H, Tasaki K, Ruetzler CA, et al. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 1997, 17:483.
121. Ginis I, Jaiswal R, Klimanis D, et al. TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappaB transactivation: The role of NF-kappaB association with p300 adaptor. J Cereb Blood Flow Metab 2002, 22:142.
122. Sherman DG The Enlimomab Acute Stroke Trial: Final results. Neurology 1997, 48:A270.
123. The Enlimomab Acute Stroke Trial Final results. Cerebrovasc Dis 1998, 7(Suppl 4):18.
124. Vuorte J, Lindsberg PJ, Kaste M, et al. Anti-ICAM-1 monoclonal antibody R6.5 (enlimomab) promotes activation of neutrophils in whole blood. J Immunol 1999, 162:2353.
125. Zhang RL, Zhang ZG, Chopp M Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 1999, 30:624.
126. Zhang R, Powers C, Zhang Z, et al. Infusion of intercellular adhesion molecule 1 antibody (18h) upregulates E- and P-selectin expression during focal embolic cerebral ischemia in rats [abstract]. Stroke 1998, 29:282.
127. Furuya K, Takeda H, Azhar S, et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: A bedside-to-bench study. Stroke 2001, 32:2665.
128. Weiner HL Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997, 18:335.
129. Chen Y, Inobe J, Marks R, et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995, 376:177.
130. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737.
131. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994, 265:1237.
132. Faria AM, Weiner HL Oral tolerance: Mechanisms and therapeutic applications. Adv Immunol 1999, 73:153.
133. Metzler B, Wraith DC Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 1996, 778:228.
134. Becker KJ, McCarron RM, Ruetzler C, et al. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U S A 1997, 94:10873.
135. Takeda H, Spatz M, Ruetzler C, et al. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive, genetically stroke-prone rats. Stroke 2002, 33:2156.
136. Alberts MJ, Bertels C, Dawson DV An analysis of time of presentation after stroke. JAMA 1990, 263:65.
137. Barone FC, Irving EA, Ray AM, et al. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther 2001, 296:312.
138. Iadecola C, Ross ME, Hsiao KK, et al. Genetically-engineered mouse mutants in studies of cerebrovascular regulation and cerebral ischemia. Mechanisms of Cerebrovascular Function and Regulation 2000, 293. Yen's Foundation, Taiwan. T.-Y. Lee, W. Pierce (Eds.).
139. Ellison JA, Barone FC, Feuerstein GZ Matrix remodeling after stroke: De novo expression of matrix proteins and integrin receptors. Ann N Y Acad Sci 1999, 890:204.
140. Hayward NJ, Elliott PJ, Sawyer SD, et al. Lack of evidence for neutrophil participation during infarct formation following focal cerebral ischemia in the rat. Exp Neurol 1996, 139:188.
141. Lapchak PA, Araujo DM, Song D, et al. Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia. Stroke 2001, 32:1220.
142. Wang X, Xu L, Wang H, et al. Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice. J Biol Chem 2002, 277:43968-43972.